Panbela Therapeutics Inc
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal ad… Read more
Panbela Therapeutics Inc (PBLA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.117x
Based on the latest financial reports, Panbela Therapeutics Inc (PBLA) has a cash flow conversion efficiency ratio of 0.117x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.12 Million) by net assets ($-18.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Panbela Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2023)
This chart illustrates how Panbela Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Panbela Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Panbela Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Instituto Rosenbusch S.A.
BA:ROSE
|
-0.133x |
|
MARKETAXESS HOLDING
MU:MWI
|
0.069x |
|
ALUMINIUM DU MAROC
BC:ALUMINIUM-DU-MAROC
|
N/A |
|
NICE CALL PUBLIC COMPANY LIMITED
BK:NCP
|
0.064x |
|
Dalrada Financial Corp
PINK:DFCO
|
0.335x |
|
Gossan Resources Ltd
V:GSS
|
-0.341x |
|
Agentix Corp
PINK:AGTX
|
-0.001x |
|
Intra Energy Corporation
AU:IEC
|
0.000x |
Annual Cash Flow Conversion Efficiency for Panbela Therapeutics Inc (2011–2023)
The table below shows the annual cash flow conversion efficiency of Panbela Therapeutics Inc from 2011 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-4.71 Million | $-25.25 Million | 5.361x | +182.46% |
| 2022-12-31 | $-8.05 Million | $-15.28 Million | 1.898x | +389.10% |
| 2021-12-31 | $10.21 Million | $-6.70 Million | -0.656x | -43.90% |
| 2020-12-31 | $8.45 Million | $-3.85 Million | -0.456x | +76.93% |
| 2019-12-31 | $1.39 Million | $-2.74 Million | -1.978x | +77.80% |
| 2018-12-31 | $268.00K | $-2.39 Million | -8.907x | -1065.81% |
| 2017-12-31 | $-3.69 Million | $-3.40 Million | 0.922x | +78.52% |
| 2016-12-31 | $-4.64 Million | $-2.40 Million | 0.517x | -64.46% |
| 2015-12-31 | $-2.68 Million | $-3.90 Million | 1.454x | +2577.39% |
| 2014-12-31 | $-210.96K | $-11.45K | 0.054x | -78.85% |
| 2013-12-31 | $-137.89K | $-35.39K | 0.257x | +128.25% |
| 2012-12-31 | $-40.85K | $37.11K | -0.909x | -603.78% |
| 2011-12-31 | $-404.99K | $-73.04K | 0.180x | -- |